Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Vivesto AB ( (SE:VIVE) ).
Vivesto AB, a Swedish oncology-focused development company listed on Nasdaq Stockholm, is advancing drug candidates for difficult-to-treat cancers in both human and veterinary medicine, including its blood cancer project Cantrixil and the Paccal Vet program for companion animals. The group is targeting areas where there is both major medical need and significant commercial opportunity.
The company has completed a rights issue of shares and a directed set-off share issue to certain guarantors, substantially increasing its share capital base. Following these transactions, Vivesto’s total number of shares and votes has risen to 1,107,136,910, a change that reshapes the firm’s ownership structure and may influence future capital market dynamics for existing and new shareholders.
More about Vivesto AB
Vivesto AB is a Swedish drug development company focused on new treatment options for hard-to-treat cancers with significant unmet medical needs and market potential. Its portfolio includes Cantrixil, in development for blood cancer, and the veterinary oncology candidate Paccal Vet, now being tested in clinical trials in dogs and cats with various tumors. Vivesto’s shares are listed on Nasdaq Stockholm under the ticker VIVE.
Average Trading Volume: 1,491,954
Technical Sentiment Signal: Sell
Current Market Cap: SEK90.79M
For a thorough assessment of VIVE stock, go to TipRanks’ Stock Analysis page.